Incretin Atlas·MoleculesTrialsOutcomesTimelinePipelineAboutMedical Adviser's Group
Incretin Atlas › Trials › STEP-HFpEF

STEP-HFpEF

Semaglutide · HFpEF + obesity

Data cut 12 November 2026 · page built 16 November 2026

Design

Molecule(s)
Semaglutide
Population
HFpEF + obesity
Official title
Research Study to Investigate How Well Semaglutide Works in People Living With Heart Failure and Obesity
Sponsor
Novo Nordisk A/S
Phase
Phase 3
Registry status
completed · 2021-03 → 2023-04
Participants
529
Duration
52 weeks
Registry
NCT04788511

Outcomes in the indication

STEP-HFpEF Semaglutide · HFpEF + obesity · 52 weeks · n = 529 seed

KCCQ-CSS +7.8 points vs placebo; weight −13.3 % vs −2.6 %

MeasureDrugControlDifference (95 % CI)Status
Body weight, percent change from baseline
week 52
−13.3−2.6−10.7 (−11.9 to −9.4) percentage pointsverified
KCCQ clinical summary score, change from baseline
week 52
+16.6+8.7+7.8 (+4.8 to +10.9) points (0-100)verified
Verbatim quotes (2)
  • Body weight, percent change from baseline
    the mean percentage change in body weight was -13.3% with semaglutide and -2.6% with placebo (estimated difference, -10.7 percentage points; 95% CI, -11.9 to -9.4; P<0.001)
  • KCCQ clinical summary score, change from baseline
    The mean change in the KCCQ-CSS was 16.6 points with semaglutide and 8.7 points with placebo (estimated difference, 7.8 points; 95% confidence interval [CI], 4.8 to 10.9; P<0.001)

Primary sources

How to cite this page

Medical Adviser's Group. Incretin Atlas: STEP-HFpEF. Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/trials/step-hfpef/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.

Cite the primary publication for any single result; every value above links to it.